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Mitogen-activated protein kinase (MAPK)-interacting kinases (Mnks) regulate the initiation of translation
through phosphorylation of eukaryotic initiation factor 4E (eIF4E). Mnk-mediated eIF4E activation promotes
cancer development and progression. While the phosphorylation of eIF4E is necessary for oncogenic
transformation, the kinase activity of Mnks seems dispensable for normal development. For this reason,
pharmacological inhibition of Mnks could represent an ideal mechanism-based and nontoxic therapeutic
strategy for cancer treatment. In this review, we discuss the current understanding of Mnk biological roles,
structures, and functions, as well as clinical implications. Importantly, we propose different strategies for
identification of highly selective small molecule inhibitors of Mnks, including exploring a structural feature
of their kinase domain, DFD motif, which is unique within the human kinome. We also argue that a combined
targeting of Mnks and other pathways should be considered given the complexity of cancer.The translational processwithin the cell has become a ‘‘hot spot’’
for cancer therapy since it became apparent that deregulation of
protein synthesis is a common event in cancer. This has stimu-
lated enthusiasm for innovative therapies targeting control over
the initiation of translation, especially the eukaryotic initiation
factor 4E (eIF4E). Given that the phosphorylation of eIF4E by
mitogen-activated protein kinase (MAPK)-interacting kinases
(Mnks) seems important for its oncogenic activity, Mnks have
emerged as potential anticancer therapeutic targets. Our previ-
ous review presented strong biological and pharmacological
evidence supporting Mnks as targets (Hou et al., 2012). As a
complementary review, we provide herein an updated overview
of the roles of Mnks in tumor biology, the rational design of
pharmacological inhibitors, and potential drug development
strategies.
The availability of eIF4E to participate in the formation of the
eukaryotic initiation complex 4F (which also consists of a scaf-
fold protein eIF4G and an RNA helicase eIF4A) is critical for initi-
ating translation of most mRNAs (Figure 1). Recognition of the
7-methyl guanosine (m7G) cap structure at the 50-UTR region
of mRNAs by eIF4E facilitates recruitment of the 43S preinitiation
complex formed by the small ribosomal unit and various initiation
factors (Rhoads, 1988). Once the small ribosomal subunit 40S is
bound to the 50-UTR of the mRNAs, it scans along the 50-leader
of the mRNA to locate the initiation codon (usually AUG). The
large ribosomal subunit 60S subsequently binds to form a
complete ribosome, which proceeds to the elongation cycle.
Given its restricted availability, eIF4E is often considered as a
rate-limiting factor for translation initiation in eukaryotic cells.
Furthermore, it has recently been demonstrated that eIF4E stim-
ulates eIF4A activity within the eIF4F complex and promotes
mRNA restructuring and translation independently of the eIF4E
cap-binding mechanism (Feoktistova et al., 2013). This might
shed light on the discriminatory effect of eIF4E on the translationChemistry & Bof capped mRNAs: physiologically, a low level of eIF4E is suffi-
cient for the translation of short, unstructured 50-UTR mRNAs,
defined as ‘‘strong’’ mRNAs, which are essential for normal
growth (e.g., b-actin) (De Benedetti and Graff, 2004); once over-
expressed, eIF4E is thought to enhance the translation of
mRNAs with a long, structured 50-UTR, known as ‘‘weak’’
mRNAs (Figure 2A). The latter encode proteins such as growth
factors (e.g., c-myc and cyclin-D1) and antiapoptotic proteins
(e.g., Bcl-2 and survivin) that play the critical roles in malignancy
and cell proliferation. Another reported role of eIF4E is to export
the mRNAs containing the 4E-sensitivity element (4E-SE) struc-
ture, i.e., cyclin-D1, to the cytoplasm (Culjkovic et al., 2007). This
process promotes the production of a variety of growth-regu-
lating proteins. Being implicated in various types of cancer,
eIF4E has become a major focus of cancer research.
The oncogenic activity of eIF4E is related to its phosphoryla-
tion by Mnks. In response to extracellular factors, Mnks are
activated by Erks and p38 kinases via phosphorylation of two
Thr residues present within the activation loop (Thr209 and
Thr214 in Mnk1 and Thr244 and Thr249 in Mnk2; vide infra;
Jauch et al., 2005, 2006; Waskiewicz et al., 1997). In the
Ras/Raf/Erks pathway, stimulated Ras activates Raf, MEK,
and Erks in series, with the latter kinases activating the Mnks
(Figure 3). The p38 subfamily of MAPKs stimulates Mnk activity
via a stress-activated cascade of kinases. Activated Mnks bind
to eIF4G, bringing the kinase and substrate into proximity
(Pyronnet et al., 1999; Shveygert et al., 2010), thus facilitating
the phosphorylation of eIF4E. To date, only two human Mnk
genes have been identified, both of which give rise to alterna-
tively spliced isoforms: Mnk1a and Mnk1b, Mnk2a and Mnk2b,
respectively (Figure 2B; O’Loghlen et al., 2004; Slentz-Kesler
et al., 2000). The four isoforms share similar N-terminal regions
that mainly contain a polybasic sequence (PBS) involved in
binding to eIF4G, but they differ in their C-termini. The Mnk1aiology 21, April 24, 2014 ª2014 Elsevier Ltd All rights reserved 441
Figure 1. Roles of eIF4E in Initiating
Translation and Exporting mRNAs from the
Nucleus to the Cytoplasm
(A) Overview of cap-dependent translation initiation:
(i) recruitment of the eIF4F complex to the 50-UTR of
the mRNA via an interaction between eIF4E and
m7G cap structure, (ii) binding of eIF4B enhances
the unwinding of the secondary structureswithin the
50-UTR, (iii) recruitment of the 43S preinitiation
complex, and (iv) localization of the initiator codon,
joining of the large ribosomal unit, and initiation of
translation.
(B) eIF4E may enhance export to the cytoplasm of
certain mRNAs that contain the 4E-SE structure.
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interaction with Erks and p38 MAPKs (Parra et al., 2005). In
contrast to Mnk1a with its high affinity for both kinases,
Mnk2a binds predominantly to Erks. The low basal activity of
Mnk1a increases after activation by Erks or p38, whereas the
constitutive, high basal activity of Mnk2a is affected only slightly
by inhibition of the upstream kinases. Notably, Mnk1a pos-
sesses a nuclear export sequence (NES) that is related to its
presence within the cytoplasm. The b-isoforms are poor sub-
strates for Erks and p38 because they lack the MAPK-binding
site within their short C-terminal region. The basal activity of
Mnk1b was found to be higher than that of Mnk2b (reviewed
in Buxade et al., 2008). Collectively, eIF4E activity is highly
regulated by Erks and p38 kinases through Mnk-mediated
phosphorylation.
In addition, eIF4E is regulated by a family of inhibitory bind-
ing proteins, named 4E-BPs, via the phosphatidylinositol 3-
kinase (PI3K)/Akt/mammalian target of rapamycin complex 1
(mTORC1) pathway (Figure 3; Pause et al., 1994). Extracellular
stimulators, i.e., mitogens, cytokines, and growth factors, trigger
a cascade of events whereby PI3K activates the 3-phosphoino-
sitide-dependent kinase 1 that promotes the activation of Akt by
phosphorylating a residue in its activation loop. Akt inactivates
tuberous sclerosis complex 1/2 (TSC1/2) through phosphoryla-
tion of TSC2. TSC2 normally acts as the GTPase-activator
protein for the GTPase Rheb. Consequently, Rheb-guanosine-
triphosphate (Rheb-GTP) accumulates, activating mTORC1 by
Rheb-GTP. 4E-BPs are normally bound strongly to eIF4E, but
their phosphorylation by mTORC1 releases eIF4E to form the
eIF4F complex (Beretta et al., 1996). Since 4E-BPs and eIF4G
share the same binding site on eIF4E, the binding of 4E-BPs to442 Chemistry & Biology 21, April 24, 2014 ª2014 Elsevier Ltd All rights reservedeIF4E prevents formation of the eIF4F
complex, thus inhibiting cap-dependent
translation.
Oncogenic Activity of eIF4E Is
Promoted by Its Antiapoptotic Effect
Elevated levels of phosphorylated eIF4E
are found in human cancer tissues ob-
tained from patients with lung, head,
colorectal, and gastric cancers and pri-
mary pancreatic ductal adenocarcinoma
(Adesso et al., 2013; Fan et al., 2009; Liang
et al., 2013). Several experiments on NIH
3T3, Chinese hamster ovary (CHO), andCREF cells showed that high levels of eIF4E were associated
with proliferation of cells and an alteration of their morphology
(reviewed in Mamane et al., 2004). Wild-type and the Trp56Ala
mutant of eIF4E were used to investigate its role in malignancy
using a mouse model in which lymphomas were generated
from Em-Myc transgenic hematopoietic stem cells (HSCs;
Wendel et al., 2007). Mice carrying wild-type eIF4E were found
to highly promote Myc-mediated lymphomagenesis, whereas
mice reconstitutedwith themutant eIF4Ewere defective in tumor
development. Knockdown of eIF4E resulted in a decreased
expression of metastasis-related proteins, such as matrix
metallopeptidase 9 (MMP9), in HER2-negative MDA-MB-231
and TM15 cells and in a reduced metastatic burden in vivo
(Nasr et al., 2013). Taken together, these data provide strong
evidence of a role for eIF4E in malignancy.
The effects of eIF4E on the cell cycle and apoptosis have also
been investigated. Silencing eIF4E led to a prolongation of the
G1 phase transition in MDA-MB-231 and TM15 cells and G0/
G1 cell cycle arrest by decreasing the translation of c-myc and
MMP9 in nasopharyngeal carcinoma cell lines (Nasr et al.,
2013; Wu et al., 2013). A similar effect was observed in
UMSCC22B cells, where cell cycle progression was disturbed
at a G1-S checkpoint when using eIF4E small interfering RNA
(Oridate et al., 2005). In addition, knockdown of eIF4E has
been shown to induce apoptotic cell death in MDA-MB-231 cells
accompanied by cleavage of the caspase 3 substrate poly
(adenosine diphosphate-ribose) polymerase (Yellen et al.,
2013). Silencing eIF4E in NIH 3T3 cells significantly reduced
the levels of antiapoptotic proteins, including BI-1, dad1, and
survivin, which explained the proapoptotic effect of eIF4E
depletion (Mamane et al., 2007). Furthermore, it increased the
Figure 2. Translational Control by Mnks
(A) eIF4E and mRNA discrimination. Translation of
strong (efficient) mRNAs (blue curve) is independent
of eIF4E, whereas translation of ‘‘weak’’ mRNAs
(purple curve) requires an increased availability of
eIF4E. Strong mRNAs code for vital proteins for
normal growth and weak mRNAs for malignancy-
related proteins as in metastasis.
(B) Regulatory features of Mnk isoforms. A solid line
represents a good affinity for the upstream kinase,
whereas a dashed line refers to a poor affinity.
Green and blue represent the N terminus and the C
terminus, respectively. The following abbreviations
were used: KD, kinase domain; MAPK, MAPK
binding site. Mnk1b and Mnk2b are poor substrates
for the MAPKs since they lack the MAPK binding
site. Mnk1a is a good substrate for both while
Mnk2a is good substrate only for Erks.
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induced apoptosis and sensitized the cells to chemotherapy
(Silva and Wendel, 2008; Zhou et al., 2011). Notably, an
increased sensitivity to fludarabine treatment was achieved
when combined with ribavirin, an m7G cap mimetic, in lympho-
cytes from patients diagnosed with primary chronic lymphocytic
leukemia (Martinez-Marignac et al., 2013). It was suggested that
ribavirin suppresses the levels of Bcl-2 induced by the single
fludarabine treatment, thus mediating cell death. Collectively,
the antiapoptotic effects of eIF4E seem important for its onco-
genic activity.
Role of Mnk Inhibition in Cancer Therapy
Mnks phosphorylate eIF4E on Ser209. It has been shown
that mice with Ser209Ala eIF4E mutant were resistant to Ras-
activated oncogenic transformation (Furic et al., 2010). Mice
carrying the ‘‘phosphomimetic’’ Ser209Asp mutant eIF4E
showed accelerated tumor onset (Wendel et al., 2007). A consti-
tutively active Mnk1 mutated at Thr332Asp was found to pro-
mote tumorigenesis in a similar way to eIF4E. These results
correlate the oncogenic activity of eIF4E with its phosphorylationChemistry & Biology 21, April 24, 201at Ser209. However, Mnks seem to be
dispensable for normal growth (Graff
et al., 2007; Ueda et al., 2004). Mnk1/2
double knockout mice have been shown
to develop normally without detectable
eIF4E phosphorylation (Ueda et al., 2004).
More recently, a study suggested that
inhibiting eIF4E phosphorylation might
differentiate between tumorigenic and
normal tissues (Lim et al., 2013). Blast
crisis (BC) chronic myeloid leukemia is
characterized by the presence of resistant
leukemia stem cells (LSCs). This is due
to an Akt-mediated elevation of b-catenin
signaling in granulocyte macrophage pro-
genitors caused by overexpression and
phosphorylation of eIF4E. Since normal
HSCs similarly require activated b-catenin
signaling, direct inhibition of b-catenin
may affect both HSCs and LSCs. How-
ever, targeting the Mnk-eIF4E axis wasshown to provide an opportunity to selectively prevent BC
LSC function in vitro and in vivo without affecting HSC function.
Inhibiting Mnk activity, therefore, might present a nontoxic
therapeutic opportunity.
The roles of Mnks in malignancy have been assessed by
several other knock-out/in models. Enhanced expression of
Mcl-1, an antiapoptotic protein, was found in Mnk1-expressing
lymphomas and correlated with the level of phosphorylated
eIF4E (Wendel et al., 2007). Knockdown of Mnk1 using small
hairpin RNA decreased the levels of phosphorylated eIF4E and
tumor formation in U87MG cells (Ueda et al., 2010). In parallel,
attenuated tumor growth was observed in Mnk1/2-double-
knockout PTEN/ mice compared to the parental PTEN/
mice. This finding indicates that inhibiting Mnks might suppress
the lymphogenesis driven by the loss of PTEN.
Despite an increased understanding of Mnk function and
related cancer biology, little progress has been made with vali-
dation of the pharmacological target. So far, only a few small
molecule inhibitors have been identified. CGP57380 and cerco-
sporamide have served as chemical biological tools, but they
lack specificity (Bain et al., 2007; Knauf et al., 2001; Konicek4 ª2014 Elsevier Ltd All rights reserved 443
Figure 3. eIF4E Is Mainly Regulated by the MAPK Pathways and the PI3K/Akt/mTOR Pathway
In response to extracellular stimuli, Mnks (especially Mnk1a) are phosphorylated by Erks or p38 MAPKs. Mnks activate eIF4E by phosphorylating it on Ser209,
which appears to promote translation initiation. Furthermore, the availability of eIF4E is regulated by the PI3K/Akt/mTOR pathway. Triggering PI3K activates
mTORC1, which in turn phosphorylates 4E-BPs and S6Ks. Hyperphosphorylated 4E-BPs bind weakly to eIF4E, releasing eIF4E to bind eIF4G and thus initiate
translation. S6Ks activate eIF4B, which enhances the helicase activity of eIF4A. TheMnk-eIF4E axis may be targeted at different stages: (1) rapalogues inhibit the
mTOR pathway, (2) 4EGI-1 impairs the binding of eIF4E to eIF4G, (3) ribavirin reportedly blocks the interaction of eIF4E with them7G cap structure of mRNAs, and
(4) Mnk inhibitors prevent the phosphorylation of eIF4E.
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other kinases, including brain-selective serine/threonine ki-
nase 2, casein kinase 1 (CK1; with a similar potency to Mnk1),
mitogen-activated protein kinase 1, and proviral integration site
3 (Pim3; Bain et al., 2007). CGP57380 blocked the phosphoryla-
tion of eIF4E in HCT-116 and B16 cell lines (Konicek et al., 2011).
However, it also inhibited rpS6 phosphorylation in Ba/F3-Bcr-
Abl and K562 cells, thus impairing polysomal assembling and
translational initiation (Zhang et al., 2008). CGP57380 induced
G1 cell arrest slightly by decreasing the expression of cyclin-
D1 and cyclin-D3 in these cell lines. Although CGP57380 has
been used to reveal the role of eIF4E phosphorylation in cancer
cell biology, the information should be interpreted with caution
(Buxade et al., 2008).
Cercosporamide is another potent Mnk inhibitor (Konicek
et al., 2011), but it also targets several other kinases, including
Janus kinase 3, glycogen synthase kinase-3b, activin-like
kinase-4 and Pim1. It has been shown to inhibit Mnk-mediated
eIF4E phosphorylation and induce apoptosis in human cancer
cell lines, including HCT-116 and B16 at a concentration
above 2.5 mM (Konicek et al., 2011). The compound has
also demonstrated antitumor efficacy in animal models.
For example, there was significant growth inhibition of human444 Chemistry & Biology 21, April 24, 2014 ª2014 Elsevier Ltd All rigMV4-11 acute myeloid leukemia (AML) tumors in animals
treated twice daily with cercosporamide at 10 mg/kg (Altman
et al., 2013).
Recent studies have shown that the cytotoxic effects of Mnk
inhibitors are cell specific and the potencies seemed to correlate
with the levels of phosphorylated eIF4E in cells. For example,
MTT experiments on human leukemia U937, MM6, or K562 cells
after treatment with cercosporamide showed a dose-dependent
suppression of the phosphorylation of eIF4E (Altman et al.,
2013). This translated to dose-dependent suppressive effects
on leukemic progenitor cell growth. In another study with six
breast cancer cell lines, phosphorylated eIF4E was readily
detectable in five of them; only MCF-7 cells displayed markedly
lower levels (Wheater et al., 2010). Long-term colony-forming
assays demonstrated that all the five cell lines having high levels
of phosphorylated eIF4E were highly sensitive to CGP57380.
These included two ERa-positive lines as well as a HER2/ERa/
PR-negative line that carries an activating k-RAS mutation. In
contrast, no inhibition of proliferation was detected in MCF-7
cells. The antiproliferative effects of CGP57380 in breast cancer
cells seemed primarily cytostatic, rather than cytotoxic, poten-
tially due to the downregulation of cyclin-D1 synthesis (Wheater
et al., 2010).hts reserved
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Pathways
Mnk inhibitors have shown enhanced antitumor activity when
combined with other protein kinase inhibitors or chemothera-
peutic agents. Although CGP57380 alone caused a partial
growth inhibition and a limited proapoptotic effect on cutaneous
T cell lymphoma cells, its combination with rapamycin, an mTOR
inhibitor, achieved complete cell growth inhibition and induced
apoptotic cell death (Marzec et al., 2011). The combined treat-
ment also inhibited cell cycle progression and suppressed the
growth of prostate cancer cells (Bianchini et al., 2008). The
combination of CGP57380 with imatinib, a Bcr-Abl inhibitor,
improved its effect on cell-cycle arrest and caspase-3-mediated
cell death in Ba/F3-Bcr-Abl and K562 cells (Zhang et al., 2008).
Similarly, treatment of pancreatic cancer cell lines MiaPaCa2
and PT45P1 with CGP57380 in combination with gemcitabine
caused a greater apoptotic cell death when compared to
the use of either CGP57380 or gemcitabine alone (Adesso
et al., 2013), again suggesting the synergistic effects of these
compounds.
A similar picture has emerged from clinical trials of therapeutic
drugs targeting the Mnk-eIF4E axis. eIF4E-specific antisense
oligonucleotides (4E-ASOs) caused a decrease in the expression
of proteins important for malignancy (e.g., cyclin-D1, c-myc, and
Bcl-2), induced apoptosis, and prevented tumor growth (Graff
et al., 2007). However, LY2275796, a 4E-ASO currently in phase
I/II clinical trials, did not give rise to any tumor response evenwith
a reduction in eIF4E mRNA of 80% within posttreatment tumor
biopsies (Hong et al., 2011). The results may reflect a less robust
downregulation of eIF4E in humans resulting in a cytostatic
effect. Based on this, the use of LY2275796 as a chemo-sensi-
tizer with chemotherapeutic agents has been proposed. Like-
wise, ribavirin inhibited the activity of eIF4E and slowed tumor
growth in a xenograft mouse model of eIF4E-dependent human
squamous cell carcinoma (Kentsis et al., 2004). It inhibited
proliferation of multiple myeloma cells by 43% and reduced
the expression of cyclin-D1 and c-myc (Li et al., 2013). Neverthe-
less, its efficacy in the M4 andM5 subtypes of AML patients was
counteracted by a molecular resistance, despite the attenuation
of eIF4E levels (Assouline et al., 2009; Borden, 2011). The utility
of combining ribavirin with a cytotoxic chemotherapeutic
agent is currently being explored in clinical trials of poor prog-
nosis AML.
Being implicated in the deregulation of protein synthesis,
eIF4E exhibits an oncogenic profile associated with its phos-
phorylation by Mnks. The role of Mnks in tumorigenesis has
been confirmed by several cancer models. Mnks have emerged
as potential effective and nontoxic anticancer targets. To date,
however, little progress has been made in the pharmacologic
target validation. Identification of highly potent and selective
Mnk inhibitors would be of importance to further our understand-
ing of Mnk-related tumor biology and therapeutic applications.
Structural Features of Mnks
Mnk kinase domain exists in the bilobal scaffold common to pro-
tein kinases: the ATP-binding site is located in a cleft between
the N-lobe and the C-lobe (Figure 4A; Jauch et al., 2005). The
N-lobe is a small hydrophobic lobe formed by antiparallel
b sheets and a regulatory aC-helix (Jauch et al., 2005, 2006).Chemistry & BHighly conserved sequence motifs are buried within the
N-lobe, including a Gly-rich loop and an AxK motif in the b3
strand. While there is 78% sequence similarity between Mnk1
and Mnk2 in their catalytic domains, the ATP binding site of
Mnk2 is more accessible to ATP or other substrates due to the
rotation of the N-lobe of Mnk2 by a further 10. The N-lobe
is connected to the C-lobe by a segment called the hinge
region, which begins at the gatekeeper residue Phe159 (Mnk2
numbering is used throughout the review unless otherwise
stated).
The C-lobe commonly encompasses six helices and com-
prises the catalytic loop and the activation segment. The activa-
tion segment consists of the magnesium binding loop, the
activation loop, and the P+1 loop (Jauch et al., 2005, 2006).
The magnesium binding loop begins, uniquely, with a DFDmotif,
instead of the DFG motif common to all other protein kinases.
The activation loop also harbors the phosphorylation sites in
Mnks, Thr244, and Thr249. Furthermore, three Mnk-specific
insertions are present within the catalytic domain (Figures 4A
and 4B): insertion I1 within the C terminus of the DFDmotif, inser-
tion I2 within the aEF/aF loop, and insertion I3 in the N terminus
of the aG-helix.
Mnks Favor an Autoinhibitory ‘‘DFD-Out’’ Conformation
One of the mechanisms that regulate kinase catalytic activity is
the conformational change of the DFG/D motif. In the inactive
state of Mnk2, the DFD motif adopts an ‘‘out’’ conformation, in
which DFD-Phe227 (Phe192 in Mnk1) inserts into the ATP-bind-
ing site, thus preventing ATP from entering this binding pocket
(Figure 4C). To date, the only wild-type Mnk1 and Mnk2 crystal
structures observed are in the DFD-out conformation. This
observation of DFG/D-out conformations is rare given that only
about 3% of kinases were captured in that conformation (Kufar-
eva and Abagyan, 2008; Zuccotto et al., 2010). For the activation
ofMnks, the DFDmotif is expected to flip to an ‘‘in’’ conformation
where the DFD-Phe227 moves away from the ATP binding site.
The active and the inactive states of kinases might also be
described in terms of spines, i.e., a regulatory spine (R-spine)
and a catalytic spine (C-spine; Kornev et al., 2006; Kornev and
Taylor, 2010; Taylor and Kornev, 2011). The spines can be
observed utilizing a local spatial-patterns alignment, a bioinfor-
matics method for comparing the spatial arrangements of pro-
tein structural elements without considering the sequence or
the geometry of the main chains of the protein. Both spines exist
only in the active conformation and are disassembled in the
inactive conformation. The R-spine bridges the N-lobe and the
C-lobe in the active state and is triggered by the phosphorylation
of the activation loop. TheC-spine also links both N- andC-lobes
and is only completed by the adenine ring of the ATP. Similar to
other kinases,Mnks are expected to form the R-spine by forming
hydrophobic interactions between four residues, two from the
N-lobe (aC-helix-Leu133 and b4 strand-Leu145) and two from
the C-lobe (HRD-His203 and DFD-Phe227). The C-spine will
include Ala111 from the AxK motif in the b3 strand, which makes
direct contact with the adenosyl ring of ATP.
The Mnk DFD-out conformation is stabilized by various inter-
actions. In Mnk2, a hydrogen bond links the amino of the
b3-Lys113 to the carbonyl of the DFD-Phe227, stabilizing the
DFD-out conformation (Jauch et al., 2005). The interactionsiology 21, April 24, 2014 ª2014 Elsevier Ltd All rights reserved 445
Figure 4. Structure of Mnks
(A) Stereoview of the structure of Mnk2 in the DFD-out conformation based on a homology model that uses the X-ray crystallographic structure (PDB ID 2AC3) as
the template (Hou et al., 2013). The hinge region backbone is shown in yellow, the three insertions in red. The DFD motif and the Phe gatekeeper are in capped
sticks.
(legend continued on next page)
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Asp273 (Asp238 in Mnk1) also help in favoring the inactive
Mnk conformations. It is believed that Mnk1 DFD-out conforma-
tion is more stable compared to Mnk2 due to several additional
interactions. Among these, the relocation of I2-Phe230 to the
DFG/D-in pocket (where the DFD-Phe192 is situated in the
DFD-in conformation) is particularly interesting. However, such
movement is unlikely in Mnk2 as I2 is located farther from the
aforementioned hydrophobic pocket.
The role of the unique DFD-Asp228 in stabilizing the DFD-out
conformation has also been studied. Mutating the DFD-Asp228
with Gly in the Mnk2 kinase region showed that Mnk2 can now
adopt both DFG-in and DFG-out conformations (Jauch et al.,
2005), presumably due to the flexibility gained by the presence
of Gly. This was further confirmed by molecular dynamics (MD)
simulation studies, where the Mnk-DFG model readily sampled
both DFG-in and DFG-out conformations (Hou et al., 2013). It
has been shown that lacking a side chain, Gly demonstrates
higher flexibility as a bipositional switch that positions the DFG
motif correctly for the active or inactive state (Kornev et al.,
2006). DFD-Asp228 is not capable of achieving such flexibility
and this may manifest as a crucial factor in favoring the DFD-out
conformation for Mnks. Observation of Mnk1 DFD-Asp193
hydrogen bonding with other residues in the DFD-out conforma-
tion, stabilizing the inactive state, only supports this notion. A
comparative study where the DFG-Gly is mutated to DFD-Asp in
a well-characterized kinase, e.g., c-Abl, might provide further in-
sights into theexact role of theDFD-Asp in theDFD-in/-out switch.
Mnk-specific insertions also contribute to the stabilization
of the inactive conformation. Residues of insertion I2, e.g.,
Glu228 and Phe230, are thought to be involved in repositioning
the activation segment into the DFD-out conformation for
Mnk1 (Jauch et al., 2006). MD simulations have been used to
investigate the role of insertion I1 (which is only four residues
away from the DFD motif) in Mnk2 during the conformational
changes (Hou et al., 2013). The authors demonstrated that an
interaction involving DFD-Asp226 and I1-Lys234 was stabilizing
the DFD-out conformation, highlighting the importance of I1 for a
favorable autoinhibitory state.
Activation of Mnks
Aswith other kinases, Mnks are expected to becomemore orga-
nized upon activation via phosphorylation, in preparation for
catalysis. It has been suggested that the interactions between
the ATP phosphates and the HRD-Arg204, which in turn disrupt
HRD-Arg204’s interaction with the aF-helix-Asp273 (Figure 4C),
are important for triggering the switch from the inactive to
active conformation (Jauch et al., 2006; Taylor and Kornev,
2011). Release of the aF-helix-Asp273 may then destabilize the
extruded conformation of the activation segment, which in turn
flips inward, facilitating a restoration of the interaction between
subdomain VIII and the aF/aG/C-loop region (Jauch et al.,(B) Sequence alignment of kinase domains of Mnks, FLT3, and c-KIT. The DFG/Dm
in line-edged boxes. The light blue background highlights conserved residues a
Mnk1/2.
(C) Stereoview of the superposition of theDFD-in (light blue) and -out (green) confo
loop and insertion 3 (I3) in the X-ray crystal structure (PDB ID 2HW7). Phe227-in
shown in yellow. All figures are generated using Pymol v.1.5.0.4.
Chemistry & B2005). Additionally, the positioning of the aC-helix has also
been shown to be a key regulatory element in protein kinase acti-
vation process (Taylor and Kornev, 2011) and a similar behavior
might be expected from Mnks. Further investigations into the
dynamical events of the activation process of Mnks would reveal
any intermediate conformations that can be exploited for
designing selective inhibitors. As such, we are currently investi-
gating these dynamic events using computational simulations.
ATP-Competitive Kinase Inhibitors
The strategies being followed for the discovery of new anticancer
agents have shifted from randomly high-throughput screening to
molecularly targeted approaches. Imatinib, the first kinase inhib-
itor to reach the market as an anticancer drug in 2001, marked
the beginning of a new era for cancer treatment—targeted can-
cer therapy. To date, fourteen kinase inhibitors have received
regulatory approval, making a considerable impact on cancer
therapy (Liu et al., 2013). The majority of kinase inhibitors are
reversible ATP-competitors and are termed type I and type II
inhibitors.
Typically, type I inhibitorsmimic the interactions of the adenine
ring of ATP with the hinge region residues of their respective
kinases (Liu and Gray, 2006). They normally bind to an active
kinase structure that is capable of binding ATP. The drawback
of this type of inhibitor is that they tend to inhibit other kinases
due to the highly conserved structure of ATP-binding domain.
This might result in off-target side effects and toxicity. A few
type I inhibitors such as VX-745 and CI-1033 have been
designed to overcome this problem by interacting with less
conserved residues within the binding site (Karaman et al.,
2008). Type II inhibitors, e.g., imatinib and BIRB-796, bind to
the inactive DFG-out structure. They bind to the ATP binding
site and to an adjacent hydrophobic binding pocket (vide infra)
that ismade accessible by the rearrangement of the DFG/Dmotif
to the DFG/D-out conformation. As there are substantial varia-
tions among the inactive conformations of kinases compared
to their ATP-activated structures, type II inhibitors are expected
to have higher selectivity compared to type I inhibitors (Zhang
et al., 2009). The DFD-out inactive form of Mnks can also be
readily exploited for designing highly selective inhibitors.
Covalent Irreversible Inhibitors
Development of covalent agents has been treated cautiously
due to their indiscriminate and irreversible binding to proteins
other than the target, therefore generating toxicity. More
recently, there has been renewed interest in the development
of irreversible kinase inhibitors that form covalent bond with
nucleophilic residue in the ATP-binding domain. These inhibitors
contain Michael acceptor-type substituent at an appropriate
position on a chemical scaffold and exploit the presence of a
cysteine residue in the ATP-binding site to establish the addition
product when bound to the enzyme (Singh et al., 2011). Byotif is shown in red, the phosphorylation sites in green, and the three insertions
mong all four kinases, and light orange the residues conserved only between
rmations ofMnk2. The homologymodel is built to include themissing activation
represents Phe227 in the DFD-in conformation of Mnk2. The hinge region is
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Figure 5. Known and Proposed Mnk Inhibitors
(A) Stereoview of X-ray structure of the bindingmode of staurosporine toMnk2 in the DFG-in conformation (PDB ID 2HW7).Mnk2 is shown as light-brown ribbons.
Staurosporine is shown in capped sticks. Hydrogen bonds are shown as dashed lines.
(B) The chemical structures of known Mnk inhibitors and proposed Mnk2 inhibitors (PI-1 and PI-2).
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irreversible inhibitors can be developed as effective therapeutic
agents with the limited off-target side effects (Serafimova et al.,
2012). Irreversible inhibitors have a number of potential advan-
tages, including prolonged pharmacodynamics, high potency,
and an ability to overcome the problem of drug resistance
when compared to their reversible counterparts.
Design of Mnk Inhibitors
Despite the increased understanding of the role of Mnks in
cancer, little progress has beenmade in the rational design of in-
hibitors. Oyarzabal et al. (2010) employed a fragment-oriented
virtual screening protocol to identify several compounds with
potent inhibitory activity against Mnks. One of these has been
shown to demonstrate a selective profile against 22 other protein
kinases. Another analog-design approach was used to develop
covalent Mnk inhibitors, although their specificity was not as-
sessed (Xu et al., 2013). The lack of progress in Mnk-targeted
drug discovery can be attributed to the absence of thorough un-
derstanding of structural details. No structural information of the448 Chemistry & Biology 21, April 24, 2014 ª2014 Elsevier Ltd All rigactivated Mnks is yet available. A staurosporine-bound crystal
structure of Mnk Asp228Gly mutant showed that the polycyclic
ring of staurosporine occupies the ATP cleft where two hydrogen
bonds are formed between the 1-NH and 5-O atoms of stauro-
sporine andGlu160 andMet162, respectively, in the hinge region
(Figure 5A; Jauch et al., 2006). These hinge region interactions
demonstrate a known bindingmode exploited by other kinase in-
hibitors. However, due to the Asp228Gly mutation, any confor-
mational changes that Asp228 might induce can remain hidden.
Thus, we generated a homology model of the wild-type DFD-in
conformation of Mnk2 (Figure 6) using Modeler (Eswar et al.,
2006). This model was selected based on the Modeler score
and Ramachandran plots, from an ensemble of 1,000 initial
models. The ATP-binding site of the chosen DFD-in model was
mapped to reveal electrostatic and steric features as shown in
Figure 6A. Themap details vital differences between the features
of the DFD-in and -out conformations that can be exploited to
tailor selective inhibitor designs. For instance, the map clearly
illustrates the size and shape of the hydrophobic pocket that
is generated in the DFD-out conformation (Figure 6B), whenhts reserved
Figure 6. Hydrogen Bond Donor/Acceptor and Hydrophobic Area Mapping of the Binding Site of Mnk2
TheMnk2 DFD-in conformation is shown in (A), and the DFD-out homology model in (B). Phe227 of the DFDmotif is shown in black and the protein backbone is in
ribbons. The yellow solid surface depicts hydrophobic areas where hydrophobic moieties of ligands could be positioned. The red and blue mesh indicates areas
where hydrogen bond acceptor and donor functionalities can be placed. The figures were generated using Site Map and Maestro (Schro¨dinger Suite 2012).
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be designed to take advantage of this hydrophobic pocket and
the unusually stable DFD-out conformation. Similar to hydropho-
bic areas, the maps also illustrate the hydrogen bond donor/
acceptor areas in the vicinity, including those of the hinge region.
To examine the binding modes of known Mnk inhibitors, the
homology model of the DFD-in conformation was used to dock
and score CGP57380, using the induced fit docking (IFD) proto-
col (Sherman et al., 2006). The docking pose reveals the
formation of strong hydrogen bonds between the 1-NH and
2-N groups of the pyrazolo[3,4-d]pyrimidine system of the
CGP57380 and the backbone of Glu160 and Met162 residues
in the hinge region of Mnk2 (Figure 7A). As demonstrated
previously, the model attests to the necessity of the 1-NH moi-
ety and its removal by methylation, e.g., compound SHN-093
(Figure 5B), would abolish the inhibition (Buxade´ et al., 2005).
However, we note some dissimilarity between the current bind-
ing mode and our previous one at the site of hinge interactions
(Hou et al., 2012). Previously, the hinge interactions were shown
through 1-NH, 2-N, and 3-NH of pyrazolo[3,4-d]pyrimidine. The
difference is most likely due to the introduction of flexibility to
the protein structure by using the IFD protocol, which allows
the identification of optimal binding modes. Additionally, in the
current binding mode, we note that the p-fluorophenyl moiety
is engaged in a p-p interaction with the gatekeeper Phe159,
providing further stabilization.
Improving Selectivity for Mnks
Information on electrostatic and steric features of the ATP bind-
ing site of Mnks can be used together with those of other kinases
to direct selective inhibitor design. Superimposing the binding
site map with the docking pose of CGP57380 suggests that a
(piperazin-1-yl)acetamide moiety can be introduced at the C4-
position, while replacing the C3-aniline moiety by a methyl group
(PI-1; Figure 5B). The binding mode generated by IFD demon-Chemistry & Bstrates that PI-1 interacts with Ser231 through the amino group
of the piperazine moiety, while maintaining the hinge interactions
seen with CGP57380 (Figure 7B). Being less conserved among
kinases, Ser231 in the activation loop of Mnk2 provides a conve-
nient stepping stone to increase potency and selectivity for
Mnk2. Although the IFD protocol was used, significant move-
ments of the protein backbone at the ATP-binding site were
not observed. This minimum reorganization required by the
protein compared to the binding conformation of a verified
Mnk inhibitor, CGP57380, provides additional confidence.
Compound PI-1 may be modified to increase selectivity
even further by targeting another partially conserved residue,
Ser166, which is positioned adjacent to the hinge region. The
proposed compound PI-2 has been designed to target Ser166
by introducing an additional butan-2-one moiety at the 4C-NH
of pyrazolo[3,4-d]pyrimidin (Figure 5B). Our binding mode sug-
gests that while PI-2 interacts with the Ser231 in a similar manner
to PI-1, the butan-2-one moiety seems engaged in a bifurcated
hydrogen bond with the hydroxyl and the backbone amino
groups of the Ser166 (Figure 7C). As PI-2 targets two residues
that are partially conserved among kinases, we expect it to be
more selective than PI-1. The fully conserved DFD-Asp228
was not targeted in our designs, as Asp228 in the current
energy-minimized homology model of the DFD-in state resolved
to an inaccessible conformation. However, as the activation
loops of kinases are highly dynamic, we cannot exclude the pos-
sibility of a DFD-in conformation where Asp228 would be acces-
sible to interaction with inhibitors. We are currently investigating
this possibility using more extensive computer simulations.
Specific protein residues may also be targeted for interaction
by irreversible inhibitors to make a covalent complex with the
protein. In the case of Mnks, this can be achieved by targeting
cysteine(s) of the binding pocket, specifically Cys190/Cys225
of Mnk1/Mnk2. For instance, resorcylic acid analogs were
recently identified as covalent Mnk inhibitors targetingiology 21, April 24, 2014 ª2014 Elsevier Ltd All rights reserved 449
Figure 7. Binding Modes of CGP57380, PI-1, and PI-2 to Mnk2
(A) Binding mode of CGP57380 to ATP-binding site and the schematic of protein-inhibitor interactions.
(B) Binding mode of the designed inhibitor PI-1. PI-1 interacts with Ser231, a partially conserved residue among kinases.
(C) Binding mode of PI-2. PI-2 interacts with Ser166 and 231, both partially conserved residues. Mnk2 is shown in light blue ribbons with the bound inhibitors in
capped sticks. Dashed lines are hydrogen bonds. The binding modes were generated computationally using the IFD protocol (Schro¨dinger Suite 2012). A
homology model of the DFD-in conformation based on an X-ray structure (PDB ID 2HW7) provided the protein atom coordinates. The ligand-interaction-diagram
tool (Schro¨dinger Suite 2012) was used to produce the interaction schematics.
Chemistry & Biology
ReviewCys225, one of the readily accessible cysteine residues for
covalent interaction in Mnk2 (Xu et al., 2013). The design
approach was based on the binding mode of hypothemycin
with Erk2 (Protein Data Bank [PDB] ID 3C9W). Alternatively, a
fragment-based approach could be employed for designing
selective Mnk inhibitors. This can be achieved by incorporating
an electrophilic group to the scaffold of an inhibitor showing a
submicromolar affinity for Mnks, e.g., CGP57380. As Cys190/
Cys225 of Mnk1/Mnk2 is conserved in 46 other kinases, hybrid450 Chemistry & Biology 21, April 24, 2014 ª2014 Elsevier Ltd All rigdesign approaches could be employed to reduce off-target
effects (Cohen et al., 2005). For instance, forming p-p interac-
tion with the gatekeeper and hydrogen bonding with unique
or partially conserved residues might offer room for improving
selectivity.
Conclusions
Significant progress has been made in understanding of the
involvement of Mnk-eIF4E in oncogenic transformation andhts reserved
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Reviewdevelopment. Strong biological evidence supports Mnks as anti-
cancer targets, but their pharmacological validation is still in
its infancy. Comprehension of Mnk kinase structural elements
would rationally guide inhibitor design and selectivity optimiza-
tion. Given the complexity of cancer, a combination ofMnk inhib-
itor with other critical pathways targeting agent(s) might be
considered as an additional therapeutic approach. However, a
promiscuous multitarget activity might pose considerable risks
due to unforeseeable side effects and toxicity. A rationally de-
signed combination therapy based on the selective inhibition
on a specific set of kinase targets would reduce these risks.
For these reasons, the discovery of highly selective Mnk inhibi-
tors will be a major step toward drug development as single-
target agents as well as combination therapeutics for cancer.ACKNOWLEDGMENTS
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